Wegovy vs Foundayo: Weekly Injection or Daily Pill
Wegovy (semaglutide, Novo Nordisk) vs Foundayo (orforglipron, Eli Lilly)
Last verified May 2026
The verdict
STEP-1 reported −14.9% at 68 weeks for Wegovy; ATTAIN-1 reported −11.1% at 72 weeks for Foundayo. Close enough that delivery and cost may decide it — but Wegovy carries the completed cardiovascular outcome, MACE −20% in SELECT, and Foundayo has no MACE data yet. That is a real asymmetry rather than a footnote: one has been shown to prevent events, the other has been shown to reduce weight. Wegovy runs $349–$499 through NovoCare; Foundayo's pricing is still landing.
Side-by-side comparison
| Field | Wegovy | Foundayo |
|---|---|---|
| Route & frequency | Subcutaneous injection, once weekly | Oral tablet, once daily — any time, with or without food |
| Mechanism | Peptide GLP-1 receptor agonist (semaglutide) | Non-peptide small-molecule GLP-1 receptor agonist |
| Weight loss (pivotal trial, max dose) | −14.9% TBWL / 68 wk (STEP-1, 2.4 mg) | −11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg) |
| FDA-approved indication | Chronic weight management; CV risk reduction in obesity + CVD | Chronic weight management; type 2 diabetes |
| Dosing schedule | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly (5-step titration) | 0.8 → 1.6 → 3 → 5.5 → 9 → 14.5 → 17.2 mg daily (7-step titration) |
| Food / timing requirement | None (injectable) | None — with or without food, any time of day |
| Whether a trial proved it prevents heart attacks and strokes | SELECT cut major cardiac events 20% in obesity without diabetes | None. No outcomes trial has reported |
| What it costs if you pay cash | $349-$499/mo through the manufacturer's direct-pay program | Direct-pay pricing was still rolling out through 2026 |
What each one costs in the compounded market
Standing monthly cash prices from the 556 sellers on this register. These are compounded preparations, not the approved products compared above.
Wegovy — semaglutide
from $79 /mo
283 sellers publish a standing price; the median is $174 a month.
Foundayo — orforglipron
from $149 /mo
2 sellers publish a standing price; the median is $149 a month.
⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.
Frequently asked questions
Which works better for weight loss, Wegovy or Foundayo?
Wegovy recorded −14.9% TBWL / 68 wk (STEP-1, 2.4 mg); Foundayo recorded −11.1% body weight / 72 wk (ATTAIN-1, 17.2 mg). ⚠ These come from separate trials with different protocols and populations, so the gap between two numbers from two studies is weaker evidence than it looks. No head-to-head trial of this pair is on record here.
Are Wegovy and Foundayo the same drug?
No. Wegovy is semaglutide and Foundayo is orforglipron — different molecules, and they work differently: Peptide GLP-1 receptor agonist (semaglutide) against Non-peptide small-molecule GLP-1 receptor agonist. Results with one do not predict results with the other.
Is Wegovy or Foundayo cheaper?
On the manufacturers' own cash pricing: Wegovy at $349-$499/mo through the manufacturer's direct-pay program, Foundayo at Direct-pay pricing was still rolling out through 2026. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.
How is each one taken?
Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly (5-step titration). Foundayo: 0.8 → 1.6 → 3 → 5.5 → 9 → 14.5 → 17.2 mg daily (7-step titration). Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.
What does a compounded version of each actually cost?
Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide from $79 a month and orforglipron from $149 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.
Can I switch from Wegovy to Foundayo?
Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.
Which one should I ask for?
That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.
References
- 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
- 3.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
- 4.Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2). N Engl J Med. 2023. PMID: 37351564.
- 5.Novo Nordisk. WEGOVY (semaglutide) injection — Prescribing Information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 6.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — Prescribing Information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
Related comparisons
- Wegovy vs Zepbound
- Ozempic vs Mounjaro
- Semaglutide vs Tirzepatide
- Rybelsus vs Ozempic
- Mounjaro vs Zepbound
- Foundayo vs Rybelsus
See the full drug-vs-drug verdict index or provider rankings.